Faraday Pharmaceuticals Analysis: $120M Raised
What is Faraday Pharmaceuticals?
Phase 3 drug to reduce heart attack damage using iodide-based therapy
Location
Seattle, United States
Employees
11-50
Founded
2014
Product Features & Capabilities
- FDY-5301 (Phase 3 clinical trial)
- Sodium iodide therapy to neutralize hydrogen peroxide
- Preclinical models showing reduced tissue damage and infarct size
Use Cases
Administer FDY-5301 during PCI for STEMI to reduce cardiac damage; Use in acute cardiac care to minimize infarct size; Apply sodium iodide therapy to reduce inflammation and tissue injury during reperfusion
Other Considerations
Phase 3 clinical trial (Iocyte AMI-3) ongoing; Completed Phase 2 trial (Iocyte AMI) with promising results; Developed by Dr. Mark Roth of Fred Hutchinson Cancer Center; Investigating sodium iodide as novel approach to ischemia-reperfusion injury
See something that needs updating? Suggest edits to this profile.